Venus Financial Statements From 2010 to 2025
| VMTHF Stock | USD 0.31 0.09 22.50% |
Check Venus Medtech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Venus Medtech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Venus financial statements analysis is a perfect complement when working with Venus Medtech Valuation or Volatility modules.
Venus |
Venus Medtech Company Return On Equity Analysis
Venus Medtech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Venus Medtech Return On Equity | -0.11 |
Most of Venus Medtech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Venus Medtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Venus Medtech has a Return On Equity of -0.1052. This is 99.56% lower than that of the Healthcare sector and 98.79% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 66.06% lower than that of the firm.
Venus Medtech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Venus Medtech's current stock value. Our valuation model uses many indicators to compare Venus Medtech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Venus Medtech competition to find correlations between indicators driving Venus Medtech's intrinsic value. More Info.Venus Medtech is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Venus Medtech's earnings, one of the primary drivers of an investment's value.About Venus Medtech Financial Statements
Venus Medtech stakeholders use historical fundamental indicators, such as Venus Medtech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Venus Medtech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Venus Medtech's assets and liabilities are reflected in the revenues and expenses on Venus Medtech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Venus Medtech. Please read more on our technical analysis and fundamental analysis pages.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Venus Pink Sheet
Venus Medtech financial ratios help investors to determine whether Venus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Venus with respect to the benefits of owning Venus Medtech security.